Depression in cancer patients

Cancer is one of the most stressful chronic diseases a person can face, and this immense

stress often takes a psychological toll. It is estimated that between 15-25% of cancer patients

will experience a mood disorder like depression during their illness and treatment.

Depression is a serious yet commonly overlooked issue that negatively impacts quality of

life, recovery, decision-making and can even influence survival rates if left untreated. As part

of high-quality, holistic cancer care, screening for depression and providing appropriate

supportive services can make a meaningful difference for patients coping with both the

disease and accompanying mental health concerns.

A cancer diagnosis introduces enormous psychological stressors including fears about the

future, uncertainty, physical changes and side effects from treatments, disruption of

relationships and life roles. Financial difficulties, existential fears and losses of confidence or

independence are additional challenges common during cancer. This trauma can trigger

clinical depression even in those without prior mental health issues. Symptoms include

persistent low or irritable mood, reduced interest/pleasure in activities, changes in appetite,

sleep disturbances, fatigue, guilt/worthlessness, trouble concentrating and recurrent thoughts

of death or suicide. Depression impairs quality of life significantly beyond the disease itself

by exacerbating physical symptoms like pain and fatigue.

There are multiple factors that determine who is most at risk of developing depression from

cancer. Having a prior history of depression or other mental illness is a strong predictor the

disease may resurface or worsen under trauma. Younger patients face disruptions to

important developmental milestones like finishing school or starting a family. Those

diagnosed with advanced or terminal cancers adapt to worse prognoses on average. High

perceived stress levels, poor social support systems, financial hardships and cognitive or

physical impairments additionally increase vulnerability. Women are twice as likely as men

to experience depression during or after cancer according to research. Factors like personality

traits, coping styles and optimism levels also influence psychological adjustment.

Recognizing depression is important as it commonly co-occurs with cancer yet remains

widely under-screened, diagnosed and treated. Unfortunately, there exists many

misconceptions that low or sad mood is a normal reaction to the significant life stress of

cancer rather than a diagnosable disorder. This prevents too many patients from receiving

timely intervention. Regular screening using validated depression scales in oncology clinics

can help identify at-risk individuals. Important screening questions assess domains like

anhedonia, changes in weight or sleep, lack of energy or concentration and suicidal thoughts.

Taking a thorough history including previous psychiatric diagnoses, support systems and

stressors provides context too. A diagnostic interview then evaluates if clinically significant

symptoms have persisted at least 2 weeks supporting a depression diagnosis.

A cancer diagnosis alone does not cause depression biologically. However, the immune

system dysregulation and inflammatory processes triggered by tumors and their treatments

contribute to higher risks. Chronic stress elevates cortisol levels long-term potentially

impacting mood pathways as well. Some cancers like brain, prostate or pancreatic tumors can

directly invade neurological structures or secrete substances exacerbating depressive

symptoms too. Certain chemotherapy agents, steroid medications, hormonal therapies or

radiation induce fatigue and cognitive impairment through neurotoxicity as potential

predisposing factors. Genetics accounts for about 40% risk of developing depression and

influences how well an individual copes with trauma. Lifestyle factors like physical

inactivity, malnutrition and social isolation further heighten vulnerability through multiple

mechanisms.

Treatment philosophies aim to reduce distress and restore function by targeting both physical

and emotional health problems together. Psychotherapy options attain this through skills

building to regulate emotions, cope adaptively with stress, improve relationships and become

more self-compassionate. Support groups harness community strength and universality to feel

less alone facing challenges. Therapies focus on changing maladaptive thought patterns,

problem-solving skills and assertiveness training via weekly sessions over 6-12 months. For

moderate-severe depression, antidepressants can be safely prescribed under oncologist

supervision. Agents usually involve selective serotonin reuptake inhibitors or other newer-

generation alternatives causing minimal side effects combined with cancer regimens.

Counseling addresses medication concerns and nonadherence risks too. Other mind-body

techniques like yoga, art/music therapy, spirituality or acupuncture provide adjunct support

for some.

Treating depression benefits various outcomes. Improved quality of life and ability to cope

reduce hospitalizations while supporting treatment adherence, doctor-patient communication

and healthcare decision-making capacity. Confronting mental anguish also allows truly

focusing remaining energy on relationships and creating meaningful experiences. Research

indicates depression remission positively impacts survival up to a year later possibly through

better self-care, healthier behaviors and immune function. Even modest symptom

improvement leads to less pain interference and greater functionality. Family/caregiver

psychological wellbeing enhances through reduced distress too. Counseling lowers costs by

addressing distress early preventing escalation requiring lengthier or higher level

interventions down the road.

Incorporating screening, early intervention and counseling as routine standards of cancer care

helps significantly. This ensures identifying psychological issues promptly to directly assist

coping rather than allowing mental health concerns to silently undermine treatment gains or

quality of remaining months. Patients with unresolved depression report feeling disregarded

by medical teams narrowly focused on physical matters. Integrated care more holistically

combines expertise through communication between oncology, psychiatry and other wellness

specialists seamlessly. This builds resilience and healthy adjustment from diagnosis through

remission or end of life transitions. Treatment decisions weigh impacts on both the body and

mind to fully empower patients and nurture emotional well-being alongside physical health.

Taking a compassionate, whole-person approach ultimately improves cancer outcomes in

meaningful ways by addressing suffering of the soul alongside suffering of the flesh.

In conclusion, depression represents a serious yet frequently under-recognized illness

impacting a sizable portion of cancer patients. The distress of receiving such a daunting

disease diagnosis and undergoing demanding therapies triggers complex psychological

mechanisms predisposing vulnerability. Untreated depression reduces quality of life

significantly through worsening physical symptoms, negatively impacting social/decision-

making capabilities and potentially diminishing survival. Regular screening,

multidimensional treatment incorporating psychotherapy, medication, mind-body tools and

integrated oncology-psychiatry care help address the condition successfully while

concurrently supporting patients' physical health, adaptation and empowerment throughout

their cancer journey. Proactively tending to mental health builds resilience promoting

wellness of both body and mind during challenging times.

Biopsychosocial model of depression

A holistic understanding of depression adopts a biopsychosocial framework recognizing

interactions between biological, psychological and social factors in its development and

course. No single cause determines the condition—rather, it evolves from an intricate

interplay of vulnerabilities. This integrative explanatory model best guides multi-modal

assessment and treatment approaches for cancer patients at heightened risk.

Biologically, neurotransmitter imbalances, neuroendocrine abnormalities, immune

dysregulation and genetic predispositions establish preconditions that interact with stressors

to trigger depression onset. The complex pathways involved implicate serotonin,

norepinephrine and dopamine systems impacted by cancer treatments as well.

Psychologically, negative cognitive styles, low self-esteem, traumatic life events like

bereavement history or learned maladaptive schemas influence perceptions of stressors along

with emotion regulation and coping strategies available. Personality traits tied to traits

pessimism or inability to experience pleasure amplify susceptibility.

Social factors encompass quality of social support networks, financial hardships, work or

family difficulties and life transitions which can exacerbate or relieve stress responses.

Lacking encouragement or feeling isolated exacerbates anxiety and gloominess.

This transactional model accepts depression arises differently based on individual biological,

cognitive-emotional vulnerabilities and social-contextual experiences. It considers lifetime

stress exposure cumulative impacts rather than single triggering events alone. This integrative

stance guides precision assessment of predisposing strengths/weaknesses along each domain

to best address maintaining or protective factors holistically. Interventions accordingly target

psychological, social and biological aspects in combination. By recognizing

multidimensional influences, providers optimize plans for each patient.

Subtypes of depression

Major depression accounts for most depression cases diagnosed through clusters of persistent

low mood and other associated cognitive, somatic and motivational symptoms reaching

clinical thresholds. However, other prominent presentations emerge among cancer

populations requiring distinct considerations:

Persistent complex bereavement relates disorder: Marked grieving and preoccupation

symptoms lasting over 12 months following loss can indicate issues adapting normally

requiring assistance moving forward functionally.

Adjustment disorder with depressed mood: Reacting with transient but clinically significant

emotion disturbances within 3 months of a significant psychosocial stressor like cancer

diagnosis can indicate vulnerable coping that needs bolstering.

Premenstrual dysphoric disorder: For reproductive-age women, severe mood symptoms

linked to menstrual cycles may be exacerbated by cancer treatment effects on hormones.

Seasonal affective disorder: Disruption of light exposure increases risks during dark winter

months that need attention, like with adjuvant phototherapy.

Cancer-related fatigue-associated affective disorder: Persistent mental/physical exhaustion

plus low mood needs energy management and functional rehabilitation strategies.

Subthreshold depression: Not meeting full diagnostic criteria, these milder depressive

symptoms still significantly impair quality of life benefiting some support.

Differentiating subtypes accurately guides individualized treatment selection sensitive to the

unique experiences, needs and trajectories involved in each presentation. Identifying nuances

facilitates appropriate level and type of intervention to optimize outcomes.

Screening and assessment

Universal screening for mood disorders improves recognition and timely support through

standardized methods shown effective and feasible in oncology settings. This involves

administering a validated depression measure on all patients with follow-up evaluations as

needed based on cutoff scores. Several reliable options exist including:

Patient Health Questionnaire-9 (PHQ-9): A 9-item scale scored 0-27 aligning assessments

with diagnostic criteria for major depression. Scores above 14 indicate severe depression.

Hospital Anxiety and Depression Scale (HADS): A 14-item measure separately evaluating

anxiety and depression symptoms, with scores of 8+ on the depression subscale meriting

attention.

Edmonton Symptom Assessment Scale (ESAS): Includes an anxiety and depression item

within broader cancer symptom monitoring gauging interfering levels from 0-10.

Distress Thermometer: Consists of a single numeric rating of overall distress accompanied by

a checklist of common problems for follow-up discussion.

These quick self- or staff-administered tools empower patients through education by naming

their experiences and improve recognition through routine monitoring that prevents

dismissing emotions as normal adaptation alone. Scores direct level and type of subsequent

comprehensive diagnostic evaluation and decisions about treatment needs. Alongside risk-

factor histories, scales sensitively gauge severity for optimal care planning.

Treatment approaches

An integrative model addressing biological, psychological and social dimensions produces

optimal depression management for cancer patients alongside medical care. Options

frequently combined include:

Psychotherapy: Focused on building coping, problem-solving, cognitive-behavioral skills and

emotional processing/acceptance to regulate distress more adaptively. Group therapy

provides extra support.

Medication: If needed based on severity/duration, psychiatrists carefully select

antidepressants less impacted by potential cancer drug interactions and side effects to target

neurotransmitters safely alongside oncology protocols.

Mind-body therapies: Stress management, yoga, meditation, massage, music or art help shift

emotional states and somatic symptoms through mind-body connections when accessible.

Lifestyle modifications: Addressing sleep hygiene, exercise, nutrition, substance use and

leisure pursuits bolster mental and physical wellness effectively.

Creative outlets: Engagement through writing, photography, gardening or spiritual practices

facilitates meaning-making and stress-reduction.

Psychoeducation: Normalizing distress and teaching concrete coping skills empowers

patients through knowledge and personal agency over emotions.

Social/family support: Improving relational health and accessing community resources like

support groups prevent isolation upholding functioning through belongingness needs.

Behavioral activation: Gently increasing engagement in enjoyable or meaningful activities

improves mood through positive reinforcement when anhedonia/fatigue occurs.

Complementary and Alternative Medicine: Natural supplements, acupuncture or energy

therapies prove beneficial adjuncts for some through relaxation and wellness enhancement

while monitored.

Selecting individually-tailored components jointly with oncology care preserves quality of

life through targeting multiple stress contributors influencing depression biologically and

psychosocially for durable remission. Psychotherapy especially shows enduring benefits post-

treatment.

Special populations

Certain groups require customized approaches considering unique experiences, access

barriers or cultural values when addressing depression:

Older adults: Functional status, cognitive or medical issues, retirement adjustment, isolation

risks necessitate age-appropriate discussions and interventions focused on meaning,

relationships and control over decisions.

Younger/childbearing patients: Disrupted life plans, infertility risks, developmental

uncertainty require assistance reprioritizing goals and transitions considerations sensitive to

lifestage.

LGBTQ+ patients: Addressing minority stress, relationship/disclosure concerns, integrated

support through G/L/B/T/Q-affirming providers promotes safe vulnerability and

belongingness needs being met.

Rural/remote communities: Overcoming geographic isolation barriers to specialty services

through telehealth/internet resources, peer navigation or community health worker programs

connect hard-to-reach populations.

Non-English speakers: Translation/interpretation facilitates during all encounters while

evaluating cultural illness perceptions, familism values or traditional healing role

functionality for comprehensive assessment.

Low SES groups: Reducing practical barriers like transportation, income disruption or health

literacy challenges through case management, funding assistance or self-help materials

prioritizes equitable access to supports available.

Tailoring appreciation for psychological diversity and specificity of needs among

demographic subsets yields empowering, meaningful support eschewing one-size-fits-all

approaches that risk harming through insensitivity, lack of cultural humility or accessibility

constraints otherwise faced.

Co-occurring disorders

Comorbid psychiatric conditions require particularly skillful coordinated care when

accompanying cancer to optimize wellbeing. Common co-occurring issues include:

Anxiety disorders: Frequently co-occurring with depression, these conditions necessitate

addressing underlying ruminations and fears comprehensively through CBT, meditation,

medication as appropriate.

Bipolar disorder: Managed via mood stabilizers under specialist oversight to prevent

destabilization through life stressors or drug interactions from medical care.

PTSD: Trauma-informed therapy targeting underlying schemas developed from cancer-

related traumatic memories through EMDR, sensorimotor or cognitive therapies effectively.

Substance use disorders: Integrated treatment considers addictive coping patterns, with

support groups especially protecting against addict transfer risks.

Personality disorders: Psychotherapy targets rigid thought-behavior patterns impacting

relationships that exacerbate distress through mentalization-based or dialectical techniques.

Psychosis: Antipsychotic medications treat serious mental illness safely alongside primary

care utilizing psychoeducation and family involvement as needed.

Addressing co-occurring conditions prevents worsening physical/emotional health due to

untreated symptoms through coordinated specialty care navigated carefully under integrated

oncology-psychiatry care. Patients gain functionality addressing interwoven mental health

needs holistically.

Caregiver depression

Loved ones caring for cancer patients themselves face burnout risks requiring consideration.

Around 20-30% of caregivers experience clinically significant mood issues from profound

impacts on time, routines, physical/emotional strength alongside witnessing a partner’s

suffering. Targeted interventions protect the wellbeing of this invaluable support system

through:

- Support groups facilitated by mental health professionals

- Psychoeducation on common distress reactions and self-care strategies

- Referrals for individual or family counseling addressing feelings, communication and goal-

setting

- Respite programs providing temporary relief from intense care responsibilities

- Case management aiding practical assistance, transportation or home services

- Screening caregiver depression routinely and treating promptly

- Involving them directly in patient treatment decisions and support planning

Prioritizing caregiver psychosocial needs sustains their caregiving ability longterm through

the most difficult periods, preventing more severe impairment and protecting family stability

integral to patient prognosis and satisfaction as well.

Recovery and post-treatment

Depression trajectories demand vigilant monitoring even after cancer treatment ends, as 10-

25% develop new or recurrent episodes years later from vulnerabilities activated initially.

Goals involve supporting:

- Healthy adjustment to post-treatment routines, bodies and self-identities

- Ongoing cancer-related worries about recurrence, infertility or cognitive changes

- Life disruptions from prolonged treatment burdens like employment impacts

- Abrupt loss of structure, support and purpose provided by medical interactions

Gradually stepping down treatment typically over 6-12 months allows consolidating skills

while addressing transitional adjustments proactively. Therapy specifically targeting re-entry

fears, relational changes or health anxiety bolsters adaptive schema reconsolidation.

Psychiatry consults mitigate risks of antidepressant discontinuation whenever cessation

occurs to prevent destabilization. Supportive therapies focused on flourishing through

survivorship optimize mental wellness maintaining hard-earned gains from care.

A well-coordinated transition plan protects against distress resurgence through continued

screening, check-ins, and guidance navigating life’s new normal after intense medical

treatment ends while recovery and stabilization remain works in progress yet. Ongoing small

gains build resilience for all future challenges hopefully never encountered again.

Palliative care considerations

For depression accompanying advanced or terminal cancers, palliative care specialists

playing a central role through enhanced attention focusing on quality as quantity of days

remaining. Key differences in approach include:

- Adjusting goals toward comfort, relationships and dignity over function/productivity

- Adopting more mindfulness-based, acceptance-focused psychotherapies

- Including grief/bereavement counseling processing approaching mortality

- Prioritizing maximizing enjoyable experiences and legacy work

- Discussing values, priorities and end-of-life choices to maintain autonomy

- Supporting whole families through difficult transitions and after losses

- Closely titrating antidepressants against side effects while maximizing symptom benefits

- Coordinating hospice care seamlessly involving pastoral/volunteer support

An empathetic, non-abandonment philosophy honors patient experiences fully guiding team

members skilled in existential discussions providing solace during life’s final challenging

chapters. Sensitively addressing depression preserves quality remaining for patients and

loved ones alike facing tremendous emotional complexity at life’s end through cancer.

In conclusion, integrating depression screening and management represents a vital

component of comprehensive, humanistic oncology care. The immense stress of cancer

predisposes significant portions of patients towards mood issues seriously impairing quality

of life when unaddressed. A biopsychosocial understanding recognizes biological,

psychological and social mechanisms interacting as vulnerabilities requiring multi-pronged

treatment ideally combined with medical care. Targeting depression holistically improves

coping and outcomes at each illness stage through survivorship. Prioritizing mental health

sustains patients’ dignity, relationships, autonomy and zest for living throughout their

journey.